Ghiyath Al-Tabbal, MD
Clinical Cardiac Electrophysiology · Wichita, KSNPI 1689890121
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Abbott at 47.8% of the total. Reporting peaked in 2020 at $7,618 and has fallen 78.1% since, to $1,669 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in KS, where the typical reported total is $20,088.
Across 364 payments — averaging $61.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Medtronic$5K
- Boehringer Ingelheim$4K
- Novartis$705
- Pfizer$700
- Kestra Medical Technology Services, Inc.$154
- plus $934 from 16 others
Across 58 payments — averaging $3642.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$118K
- Medtronic$90K
- Boston Scientific$4K
What the payments were for
- Consulting fees$9,61243%
- Speaking & faculty fees$3,55016%
- Travel & lodging$3,36615%
- Food & beverage$5,80526%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 47 | $10,714 |
| Medtronic(2 entities) | 67 | $4,944 |
| Boehringer Ingelheim | 60 | $4,255 |
| Novartis | 53 | $705 |
| Pfizer | 72 | $700 |
| Kestra Medical Technology Services, Inc. | 2 | $154 |
| Merck | 13 | $145 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $128 |
| Johnson & Johnson | 7 | $103 |
| E.r. Squibb & Sons, L.L.C. | 6 | $95 |
| Boston Scientific | 4 | $65 |
| Amgen | 3 | $59 |
| Cvrx, Inc. | 4 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| AstraZeneca | 3 | $42 |
| Bayer | 2 | $40 |
| Lexicon Pharmaceuticals, Inc. | 2 | $40 |
| Novo Nordisk | 2 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $33 |
| Lundbeck LLC | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $18 |
| Surmodics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$7,092
- PRADAXA$3,550
- EnSite Precision Cardiac Mapping System$2,385
- Micra$1,929
- AVEIR$657
- ASSURITY$156
- Assure WCD$127
- ENSITE$106
How this compares
$22,406 in reported general payments places this provider in the 50th percentile of 37 clinical cardiac electrophysiology providers in Kansas.
See all clinical cardiac electrophysiology providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 921 | $909,449 |
| EntrestoSacubitril/Valsartan | 654 | $634,175 |
| XareltoRivaroxaban | 291 | $303,732 |
| JardianceEmpagliflozin | 334 | $243,323 |
| FarxigaDapagliflozin Propanediol | 100 | $77,578 |
| Flecainide Acetate | 1,226 | $41,744 |
| MultaqDronedarone Hcl | 36 | $35,199 |
| BrilintaTicagrelor | 29 | $29,364 |
| OzempicSemaglutide | 14 | $13,547 |
| Repatha SureclickEvolocumab | 16 | $12,345 |
| Repatha SyringeEvolocumab | 16 | $11,716 |
| VerquvoVericiguat | 11 | $8,149 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 33 | $7,835 |
| Nebivolol Hcl | 157 | $7,465 |
| SotalolSotalol Hcl | 475 | $7,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $700 | $909,449921 claims |
| NovartisEntresto | $705 | $634,175654 claims |
| Johnson & JohnsonXarelto | $103 | $303,732291 claims |
| Boehringer IngelheimJardiance | $4,255 | $243,323334 claims |
| AstraZenecaFarxiga, Brilinta | $42 | $106,941129 claims |
| Sanofi-aventis U.S. LLCMultaq | $44 | $35,19936 claims |
| Novo NordiskOzempic | $36 | $13,54714 claims |
| MerckVerquvo | $145 | $8,14911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 37 clinical cardiac electrophysiology providers in Kansas.
Other clinical cardiac electrophysiology in Wichita
- Olakanmi OlagokeWichita$42K
- Amit KoduriWichita$39K
- Dhaval ParikhWichita$11K
- Christos MandanisWichita$10K
- P MargolisWichita$7K
- Jesus Val MejiasWichita$2K
- Ashok BajajWichita$141
- Dhanunjaya LakkireddyKansas City$1.1M
- Rakesh GopinathannairOverland Park$425K
- Rhea PimentelKansas City$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.